Diabetes device firm Beta Bionics slides on $125 mln stock offering plans

Senseonics Holdings

15/09/2026 21:48

** Insulin delivery device maker Beta Bionics' BBNX.O shares down 6.1% post-market to $18.05 as it seeks equity raise
** Irvine, California-based BBNX announces $125 mln stock offering
** Co intends to use net offering proceeds for general purposes, including costs associated with commercialization of Mint, expansion of manufacturing facilities, R&D and clinical development, among other uses
** JP Morgan, Piper Sandler, Wells Fargo and Leerink joint bookrunners
** BBNX shares closed up 14.9% at $19.23 on Tues, reducing YTD loss to ~37%
** Co early Mon said the U.S. FDA cleared Mint, its transformative patch pump, and expects to commercially launch it Q1 2027
** Also early Mon, Senseonics SENS.O announced partnership to integrate its Eversense 365 CGM with BBNX's iLet Bionic Pancreas system
     ** BBNX has ~45 mln shares outstanding for about $865 mln market cap; it went public in Jan 2025 IPO priced at $17
** Avg rating of 12 analysts is "buy"; median PT $22, per LSEG

(Lance Tupper is a Reuters market analyst. The views expressed are his own)
((lance.tupper@tr.com 1-646-279-6380))